To determine the relation between benefit from fibrinolytic therapy and treatment delay (time between onset of symptoms and treatment) for mortality from myocardial infarction (MI).
primary studies according to defined criteria. As the authors correctly state, there may be sources of bias in the review such as differences in the baseline characteristics between time-to-treatment groups, the unknown delay between randomisation and actual initiation of therapy, and the individual delays within studies. It is not possible to comment on the generalisability of the results given the limited literature search and the lack of validity criteria applied to the primary studies.
